Literature DB >> 6163499

Beta 2-microglobulin in haematological malignancies.

.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1981        PMID： 6163499      PMCID： PMC1504900          DOI： 10.1136/bmj.282.6269.1013

Source DB:  PubMed          Journal:  Br Med J (Clin Res Ed)        ISSN： 0267-0623


× No keyword cloud information.
  12 in total

1.  Serum beta 2 microglobulin and its prognostic value in lymphomas.

Authors:  P L Amlot; M Adinolfi
Journal:  Eur J Cancer       Date:  1979-05       Impact factor: 9.162

2.  Serum beta 2 microglobulin and C-reactive protein in the monitoring of lymphomas: findings in a multicenter study and experience in selected patients.

Authors:  J A Child; B Spati; S Illingworth; D Barnard; S Corbett; A V Simmons; J Stone; T S Worthy; E H Cooper
Journal:  Cancer       Date:  1980-01-15       Impact factor: 6.860

3.  Serum beta 2-microglobulin in acute and chronic leukaemia.

Authors:  J Ellegaard; C E Mogensen; K Kragballe
Journal:  Scand J Haematol       Date:  1980-09

4.  Serum beta 2-microglobulin, serum creatinine and bone marrow plasma cells in benign and malignant monoclonal gammopathy.

Authors:  A Morell; W Riesen
Journal:  Acta Haematol       Date:  1980       Impact factor: 2.195

5.  Diagnosis of leukemia or lymphoma in the central nervous system by beta 2-microglobulin determination.

Authors:  G M Mavlight; S E Stuckey; F F Cabanillas; M J Keating; W W Tourtellotte; S C Schold; E J Freireich
Journal:  N Engl J Med       Date:  1980-09-25       Impact factor: 91.245

6.  Behaviour of serum beta 2-microglobulin and acute phase reactant proteins in chronic lymphocytic leukaemia. A multicentre study.

Authors:  B Späti; J A Child; S M Kerruish; E H Cooper
Journal:  Acta Haematol       Date:  1980       Impact factor: 2.195

7.  Beta 2-microglobulin in chronic lymphocytic leukaemia.

Authors:  B Simonsson; L Wibell; K Nilsson
Journal:  Scand J Haematol       Date:  1980-02

8.  Serum beta 2-microglobulin in malignant and benign diseases of the stomach and pancreas.

Authors:  S A Rashid; E H Cooper; A T Axon; G Eaves
Journal:  Biomedicine       Date:  1980 Jul-Aug

9.  A clinical staging system for multiple myeloma. Correlation of measured myeloma cell mass with presenting clinical features, response to treatment, and survival.

Authors:  B G Durie; S E Salmon
Journal:  Cancer       Date:  1975-09       Impact factor: 6.860

10.  Serum beta 2-microglobulin in myelomatosis: potential value in stratification and monitoring.

Authors:  D Norfolk; J A Child; E H Cooper; S Kerruish; A M Ward
Journal:  Br J Cancer       Date:  1980-10       Impact factor: 7.640
View more
  2 in total

1.  Beta-2 microglobulin: a sensitive non-specific marker for acquired immune deficiency syndrome.

Authors:  P Francioli; F Clément; M P Glauser
Journal:  Eur J Clin Microbiol       Date:  1984-02       Impact factor: 3.267

2.  Factors influencing serum neopterin and beta 2-microglobulin levels in a healthy diverse population.

Authors:  L S Diamondstone; D J Tollerud; D Fuchs; H Wachter; L M Brown; E Maloney; C C Kurman; D L Nelson; W A Blattner
Journal:  J Clin Immunol       Date:  1994-11       Impact factor: 8.317
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.